| Filed On | Filing |
|---|---|
| 17 Oct 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The Board of Directors of Allogene Therapeutics, Inc. (the “Company”) appointed Geoffrey Parker as the Company’s Executive Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective O... |
| 26 Oct 2020 | 8-K/A: Submission of Matters to a Vote of Security Holders |
Loading...
